{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:37:01Z","timestamp":1760060221228,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>(1) Background: Atrial fibrillation (AF) is the most common arrhythmia and poses a clinical dilemma in the very elderly due to increased thromboembolic and bleeding risks. This study aimed to evaluate clinical outcomes\u2014including thromboembolic events, major bleeding, and all-cause mortality\u2014by age group in elderly East Asian patients with non-valvular AF receiving oral anticoagulants. (2) Methods: This retrospective single-center study included 502 patients aged \u226570 years treated with direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, edoxaban, or apixaban) or warfarin between 2016 and 2024. Patients were stratified into two age groups: 70\u201379 and \u226580 years. The primary outcomes were ischemic stroke, systemic thromboembolism, and major bleeding. (3) Results: Although patients aged \u226580 years showed a numerically higher incidence of bleeding in both the DOAC and warfarin groups, these differences were not statistically significant after multivariable adjustment (DOAC group: HR 0.832; 95% CI, 0.456\u20131.518; p = 0.549; warfarin group: HR 3.617; 95% CI, 0.600\u201321.804; p = 0.161). Ischemic and thromboembolic event rates were also comparable between age groups. (4) Conclusions: Despite a numerically higher bleeding risk in the very elderly, DOACs remained safe and effective when appropriately managed. These findings support individualized anticoagulation decisions based on clinical factors rather than age alone in elderly East Asian patients with AF.<\/jats:p>","DOI":"10.3390\/life15081298","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:33:42Z","timestamp":1755254022000},"page":"1298","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Oral Anticoagulation in Elderly East Asian Patients with Atrial Fibrillation: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4992-3224","authenticated-orcid":false,"given":"Kyunyeon","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"},{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-6485","authenticated-orcid":false,"given":"YouMi","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"},{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6366-0143","authenticated-orcid":false,"given":"Sang-Suk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"},{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunjoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"},{"name":"Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Jun","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungjae","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Seoul 16247, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Oancea, A.F., Jigoranu, R.A., Morariu, P.C., Miftode, R.S., Trandabat, B.A., Iov, D.E., Cojocaru, E., Costache, I.I., Baroi, L.G., and Timofte, D.V. (2023). Atrial Fibrillation and Chronic Coronary Ischemia: A Challenging Vicious Circle. Life, 13.","DOI":"10.3390\/life13061370"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Scharf, R.E. (2021). Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071530"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e017024","DOI":"10.1161\/JAHA.120.017024","article-title":"Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation","volume":"9","author":"Dalgaard","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chest.2019.11.025","article-title":"Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study","volume":"157","author":"Chao","year":"2020","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.15-1095","article-title":"Clinical Characteristics and Outcomes in Extreme Elderly (Age >\/= 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry","volume":"149","author":"Yamashita","year":"2016","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/1570161116666180117103238","article-title":"Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?","volume":"16","author":"Bae","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast asian paradox\u201d: Challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Jeong","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","article-title":"Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation\u2014An ENGAGE AF-TIMI 48 Subanalysis","volume":"80","author":"Yamashita","year":"2016","journal-title":"Circ. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1080\/03007995.2018.1478282","article-title":"Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: A propensity-matched analysis from Japanese administrative claims data","volume":"34","author":"Kohsaka","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/europace\/eux247","article-title":"Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation","volume":"19","author":"Lee","year":"2017","journal-title":"Europace"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2019-315065","article-title":"Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation","volume":"106","author":"Wu","year":"2020","journal-title":"Heart"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joa.2016.11.003","article-title":"Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry","volume":"33","author":"Okumura","year":"2017","journal-title":"J. Arrhythm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: Observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review","volume":"10","author":"Wilke","year":"2017","journal-title":"Patient"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/8\/1298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:28:07Z","timestamp":1760034487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/8\/1298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["life15081298"],"URL":"https:\/\/doi.org\/10.3390\/life15081298","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}